Vascular Flow Technologies presented data at the 41st Annual VEITHsymposium on Vascular and Endovascular Issues in New York, showing a 30% increase in one-year success for infrainguinal vascular bypass surgery in patients who received a Spiral Flow graft compared to those who received a standard polytetrafluoroethylene (PTFE) graft.
The study shows one-year primary and secondary patency rates of 76% and 87% for Spiral Flow grafts (n=54), compared to 48% and 55% for PTFE bridge graft (n=124), as well as a lower amputation rate in patients receiving Spiral Flow grafts (2% vs 10%).
The study was led by Nick Shaper, consultant vascular surgeon at Bradford Royal Infirmary, UK. Shaper said: “All patients demonstrated post-operative spiral laminar flow at the distal anastomosis, and there was a substantial and highly encouraging improvement in one-year patency rates in this group of patients.”
Spiral laminar flow technology is the only vascular graft technology that is proven to replicate natural blood flow by generating a spiral laminar flow within the graft, reducing turbulence at the point where the blood flows into the blood vessel, which limits changes to the blood vessel wall that may be precursors to thrombosis.
The VEITHsymposium also heard from Richard Neville, chief of the Division of Vascular Surgery, George Washington University Hospital. Neville presented an update on the newly-opened US registry for Spiral Flow arteriovenous grafts in haemodialysis access. The Spiral Flow Arteriovenous Access Graft Clinical Registry will collect the primary, primary assisted and secondary patency rates of the Spiral Flow arteriovenous access graft in patients with end stage renal disease as well as recording complication rates.
The registry will provide data to its physician users detailing their patients’ graft performance data compared to national performance. The registry will hold demographic, operative and postoperative graft performance data, and results. Findings will be presented at future local, regional and national vascular conferences.
Bill Allan, chief executive officer of Vascular Flow Technologies commented: “Clinical experience with Spiral Flow grafts is continuing to grow, and the newly opened US registry will provide a further bank of data for evaluation of long-term patency and complication rates. We are encouraging haemodialysis physicians to view the portal and to seek Institutional Review Board approval to start entering patient data.”
